A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
A single treatment with a CRISPR-Cas9 based gene editing therapy is enough to replace the daily medication of patients with hereditary angioedema (HAE), a condition characterized by severe, painful ...
Philadelphia and Gordonville, PA, August 12, 2025 – Researchers from Children’s Hospital of Philadelphia (CHOP) and the Clinic for Special Children found that complement factor I (CFI) deficiency, an ...
Hereditary angioedema (HAE) is diagnosed through blood tests that measure complement protein (C4) and complement inhibitor (C1-INH) levels. Low C4 levels strongly suggest HAE, especially during an ...
Credit: Getty Images. CHAPLE disease is a rare genetic disorder caused by mutations in the CD55 gene. The Food and Drug Administration (FDA) has accepted for Priority Review the Biologics License ...
Global biopharma company encourages education and awareness around a rare bleeding disorder. FORT LEE, N.J., Oct. 10, 2023 /PRNewswire/ -- Kedrion Biopharma, an international biopharmaceutical company ...
Given the heterogeneity and rarity of inborn errors of immunity (IEIs), management guidelines that deal with primary immunodeficiency as a whole are rare. The most recent general guideline, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results